A Phase 2 interventional study of C21 in Idiopathic Pulmonary Fibrosis, sponsored by Vicore Pharma AB. Completed at 21 sites in 4 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by Vicore Pharma AB · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Idiopathic Pulmonary Fibrosis with a site in India — 1 open to participants now, 5 under way, 3 of them phase 3. Idiopathic Pulmonary Fibrosis · India.
Among the 12 studies in Idiopathic Pulmonary Fibrosis with a site in India, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 2, and was the 6th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →1 of the 12 studies in Idiopathic Pulmonary Fibrosis with a site in India is open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in India, United States, Argentina and 24 more countries
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 5
First in 2012; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is close to the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 274 across the 11 interventional studies, 21 across the 1 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 8 most frequent:
Vicore Pharma AB is the lead sponsor of 11 studies on the registry; none are open to participants now.
Vicore Pharma AB has 3 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Idiopathic Pulmonary Fibrosis with a site in India that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Idiopathic Pulmonary Fibrosis with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial is a multi-centre, open-label, single-arm phase 2 trial investigating the safety, efficacy and pharmacokinetics of C21 in subjects with idiopathic pulmonary fibrosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
High-resolution computed tomography (HRCT) within 36 months prior to Visit 1 with central reading demonstrating either a or b, and c:
a. A pattern consistent with usual interstitial pneumonitis (UIP) according to ATS/ERS/JRS/ALAT or Fleischner guidelines i. UIP ii. Probable UIP or b. A pattern indeterminate for UIP according to either ATS/ERS/JRS/ALAT or Fleischner guidelines and a historical consistent with IPF c. Extent of fibrosis > extent of emphysema
Exclusion Criteria:
IPF exacerbation within 3 months prior to Visit 1:
Treatment with any of the medications listed below within 4 weeks prior to Visit 1:
Treatment with any of the medications listed below within 2 weeks prior to Visit 1:
Any of the following findings at Visit 1:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
C21 100 mg BID (twice daily)
Drug: C21
C21 100 mg BID (twice daily)
Also known as: Buloxibutid, Compound 21
Number of Participants With Adverse Events Occurring Over the Trial Period
Number of participants with adverse events occurring over the trial period incl. number of participants with any TEAE, serious TEAEs, TEAEs leading to withdrawal from trial, TEAEs leading to discontinuation of treatment, treatment-related TEAEs leading to discontinuation of treatment, TEAEs leading to death, and serious treatment-related TEAEs. Adverse events were recorded from signing of informed consent until end of trial. Nature and frequency of adverse events are presented in details in the adverse events section.
Time frame: Trial period of 36 weeks
Change From Baseline in Forced Vital Capacity (Non-imputed Data)
Mean changes in forced vital capacity (FVC) (mL) from baseline to week 12, week 24, and week 36 were calculated
Time frame: 12, 24, and 36 weeks
Change From Baseline in Forced Vital Capacity (Imputed Data)
Mean changes in forced vital capacity (FVC) (mL) from baseline to week 12, week 24, and week 36 were calculated
Time frame: 12, 24, and 36 weeks
Rate of Forced Vital Capacity Decline Over Time, FAS
Model-based mean (90% CI) FVC changes over 12, 24, and 36 weeks were normalized to change over 24 weeks. A piece-wise linear regression model with knots at weeks 6 and 24 and unstructured covariance matrix was fitted to change from baseline data. Knot selection was performed by visual inspection. The model based change over 12, 24, and 36 weeks was normalized to represent a change over 24 weeks. Rate of decline was computed as y(t) - y(0) = t\*Beta1 + max(0, t-6)\*Beta2 + max(0,t-24)\*Beta3, adjusted to show the decline per 24 weeks, where y is the value at the respective week and Beta is the model coefficient. No imputation of data was conducted.
Time frame: 12, 24, and 36 weeks
Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Day 1
The plasma concentration of C21 (ng/mL) was calculated in a subset of subjects at specified timepoints post-dose.
Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose on Day 1
Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 12
The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 12 weeks of dosing.
Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Week 12
Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 24
The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 24 weeks of dosing.
Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Week 24
Plasma Concentration of C21 Evaluated in a Sub-set of Subjects, Week 36
The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 36 weeks of dosing.
Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Week 36
Cmax in a Sub-set of Subjects
The maximal plasma concentration (Cmax (ng/ml)) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing
Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36
Tmax in a Sub-set of Subjects
The time for the maximal plasma concentration (Tmax (h)) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing
Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36
AUClast in a Sub-set of Subjects
Area under the plasma concentration time curve to the last quantified concentration (AUClast) (h\*ng/mL) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing
Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36
Accumulation Ratio AUC in a Sub-set of Subjects
Accumulation ratio AUC was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing
Time frame: Prior to dosing, 30 min post dose, 1 h post dose, 2 h post dose, 3 h post dose, and 4 h post dose at Weeks 0, 12, 24, and 36
| Milestone | C21 100 mg BID |
|---|---|
| Started | 52 |
| Completed | 27 |
| Not completed | 25 |
| Withdrew: Withdrawal by subject | 15 |
| Withdrew: Adverse event | 6 |
| Withdrew: Death | 1 |
| Withdrew: Fvc decline and fvcpp<60% | 2 |
| Withdrew: Fvc decline, fvcpp<60% and worsening of respiratory symptoms | 1 |
Number of participants with adverse events occurring over the trial period incl. number of participants with any TEAE, serious TEAEs, TEAEs leading to withdrawal from trial, TEAEs leading to discontinuation of treatment, treatment-related TEAEs leading to discontinuation of treatment, TEAEs leading to death, and serious treatment-related TEAEs. Adverse events were recorded from signing of informed consent until end of trial. Nature and frequency of adverse events are presented in details in the adverse events section.
| Participants | C21 100 mg BID, SAS |
|---|---|
| Total number of subjects with treatment-emergent adverse events (TEAEs) | 37 |
| Total number of subjects with serious TEAEs | 5 |
| Total number of subjects with TEAEs leading to withdrawal from study | 6 |
| Total number of subjects with TEAEs leading to discontinuation of treatment | 12 |
| Total number of subjects with treatment-related TEAEs leading to discontinuation of treatment | 3 |
| Total number of subjects with TEAEs leading to death | 2 |
| Total number of subjects with serious treatment-related TEAEs | 0 |
Mean changes in forced vital capacity (FVC) (mL) from baseline to week 12, week 24, and week 36 were calculated
| mL | C21 100 mg BID |
|---|---|
| Week 12 | -4.9 (-73.2 to 63.4) |
| Week 24 | 16.0 (-117.4 to 149.3) |
| Week 36 | 216.0 (36.9 to 395.1) |
Mean changes in forced vital capacity (FVC) (mL) from baseline to week 12, week 24, and week 36 were calculated
| mL | C21 100 mg BID |
|---|---|
| Week 12 | -57.6 (-123.3 to 8.1) |
| Week 24 | -70.3 (-170.5 to 29.9) |
| Week 36 | 9.4 (-115.6 to 134.4) |
Model-based mean (90% CI) FVC changes over 12, 24, and 36 weeks were normalized to change over 24 weeks. A piece-wise linear regression model with knots at weeks 6 and 24 and unstructured covariance matrix was fitted to change from baseline data. Knot selection was performed by visual inspection. The model based change over 12, 24, and 36 weeks was normalized to represent a change over 24 weeks. Rate of decline was computed as y(t) - y(0) = t\*Beta1 + max(0, t-6)\*Beta2 + max(0,t-24)\*Beta3, adjusted to show the decline per 24 weeks, where y is the value at the respective week and Beta is the model coefficient. No imputation of data was conducted.
| mL | C21 100 mg BID |
|---|---|
| Week 12 | -8.2 (-141.9 to 125.5) |
| Week 24 | 36.4 (-87.1 to 160) |
| Week 36 | 108.9 (-4.8 to 222.6) |
The plasma concentration of C21 (ng/mL) was calculated in a subset of subjects at specified timepoints post-dose.
| ng/mL | C21 100 mg BID |
|---|---|
| Prior to dosing | 5.00 ± 0.00 |
| 30 min post dose | 1622.0 ± 1453.64 |
| 1 h post dose | 1788.11 ± 1112.48 |
| 2 h post dose | 864.46 ± 1062.15 |
| 3 h post dose | 322.19 ± 407.29 |
| 4 h post dose | 282.82 ± 379.31 |
The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 12 weeks of dosing.
| ng/mL | C21 100 mg BID |
|---|---|
| Prior to dosing | 27.13 ± 62.58 |
| 30 min post dose | 974.28 ± 1028.90 |
| 1 h post dose | 1044.02 ± 1128.30 |
| 2 h post dose | 794.02 ± 774.34 |
| 3 h post dose | 491.25 ± 820.36 |
| 4 h post dose | 101.50 ± 113.96 |
The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 24 weeks of dosing.
| ng/mL | C21 100 mg BID |
|---|---|
| Prior to dosing | 20.14 ± 28.608 |
| 30 min post dose | 615.53 ± 792.908 |
| 1 h post dose | 898.61 ± 779.723 |
| 2 h post dose | 404.80 ± 296.002 |
| 3 h post dose | 151.30 ± 125.292 |
| 4 h post dose | 115.93 ± 151.833 |
The plasma concentration of C21 (ng/mL) was calculated at specified timepoints post-dose after 36 weeks of dosing.
| ng/mL | C21 100 mg BID |
|---|---|
| Prior to dosing | 89.78 ± 176.452 |
| 30 min post dose | 796.29 ± 839.353 |
| 1 h post dose | 713.86 ± 453.540 |
| 2 h post dose | 298.29 ± 299.235 |
| 3 h post dose | 374.16 ± 459.545 |
| 4 h post dose | 348.11 ± 479.786 |
The maximal plasma concentration (Cmax (ng/ml)) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing
| ng/mL | C21 100 mg BID |
|---|---|
| 0 Weeks | 1852.13 ± 80.1 |
| 12 Weeks | 954.29 ± 127.9 |
| 24 Weeks | 524.79 ± 281.6 |
| 36 Weeks | 961.86 ± 73.3 |
The time for the maximal plasma concentration (Tmax (h)) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing
| h | C21 100 mg BID |
|---|---|
| Week 0 | 1.00 (0.5 to 4.0) |
| Week 12 | 1.50 (0.5 to 4.0) |
| Week 24 | 1.00 (0.0 to 1.0) |
| Week 36 | 1.00 (0.5 to 4.00) |
Area under the plasma concentration time curve to the last quantified concentration (AUClast) (h\*ng/mL) was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing
| h*ng/mL | C21 100 mg BID |
|---|---|
| Week 0 | 3018.151 ± 60.5 |
| Week 12 | 1704.924 ± 126.6 |
| Week 24 | 995.600 ± 213.2 |
| Week 36 | 1622.774 ± 49.8 |
Accumulation ratio AUC was calculated in a subset of subjects after 0, 12, 24, and 36 weeks of dosing
| Ratio | C21 100 mg BID |
|---|---|
| Week 12 | 0.84598 ± 120.5 |
| Week 24 | 0.45256 ± 328.9 |
| Week 36 | 0.73765 ± 67.9 |
Collected over Throughout the trial from signing of informed consent until the end-of-trial visit, up to 44 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| C21 100 mg BID | 2/52 (3.8%) | 5/52 (9.6%) | 35/52 (67.3%) |
| Event | C21 100 mg BID |
|---|---|
| Angina pectorisCardiac disorders | 1/52 |
| Cardiac failureCardiac disorders | 1/52 |
| COVID-19Infections and infestations | 1/52 |
| Kidney infectionInfections and infestations | 1/52 |
| SepsisCardiac disorders | 1/52 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 1/52 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/52 |
| Type 2 diabetes mellitusMetabolism and nutrition disorders | 1/52 |
| Squamous cell carcinoma of the oral cavityNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/52 |
| Event | C21 100 mg BID |
|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 10/52 |
| RashSkin and subcutaneous tissue disorders | 4/52 |
| Gastro-oesophageal reflux diseaseGastrointestinal disorders | 4/52 |
| Blood creatinine increasedInvestigations | 4/52 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/52 |
| PyrexiaGeneral disorders | 4/52 |
| DiarrhoeaGastrointestinal disorders | 3/52 |
| C-reactive protein increasedInvestigations | 3/52 |
| Lower respiratory tract infectionInfections and infestations | 3/52 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/52 |
| Age, Continuous(Years) | C21 100 mg BID, SAS |
|---|---|
| Mean | 67.3 ± 9.38 |
| Sex: Female, Male(Participants) | C21 100 mg BID, SAS |
|---|---|
| Female | 12 |
| Male | 40 |
| Ethnicity (NIH/OMB)(Participants) | C21 100 mg BID, SAS |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 52 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | C21 100 mg BID, SAS |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 38 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | C21 100 mg BID, SAS |
|---|---|
| Ukraine | 4 |
| United Kingdom | 7 |
| India | 38 |
| Russia | 3 |
| Height(cm) | C21 100 mg BID, SAS |
|---|---|
| Mean | 161.69 ± 8.723 |
| Weight(kg) | C21 100 mg BID, SAS |
|---|---|
| Mean | 64.64 ± 14.178 |
| Body mass index(kg/m^2) | C21 100 mg BID, SAS |
|---|---|
| Mean | 24.57 ± 4.119 |
12 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2020 to primary completion in Mar 2024, 40 months.
Results were first posted in May 2025, 1 year 1 month after primary completion.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's 40 months is above that.
Counting every sponsor, half of 76 studies reached it within 29 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Compound 21
Idiopathic Pulmonary Fibrosis →
Vicore Pharma AB